| ≥1 piece |
Insulin sensitizer- buckwheat extract for diabetes
Product Introduction
Insulin enters the blood circulation and acts on the various organs and tissues to regulate glucose metabolism. Insulin binds to its specific cell surface receptors, activates a complex signal transduction pathway, and eventually leads to the opening of cell surface channels that take up glucose from the blood stream. The end result is the lowering of the blood glucose level.
Any blockade or efficiency decrease in this signaling pathway will result in compromised insulin action, affecting insulin?s ability to regulate blood glucose. This is called insulin resistance. To compensate the decreased insulin sensitivity, human body produces more and more insulin. This leads to hyper-insulinia. The sustained high insulin level in the blood have detrimental effects on other metabolic processes, such as lipid metabolism and sex hormone metabolism. The broad category of human diseases resulting from insulin resistance is called X Syndrome and includes diabetes, high blood pressure, obesity, stroke, PCOS, etc.
Researches carried out in the last two decades at various laboratories have indicated that inositol molecules, particularly D-chiro-inositol and Myo-inositol, are important mediators for insulin action.
D-chiro-inositol was found to be present in the urine and blood of normal people but absent or at much reduced level in those of Type 2 diabetic patients, suggesting that Type 2 diabetic patients may not produce enough Inositol A and therefore exhibit a decrease in insulin sensitivity.
Results from several laboratories have demonstrated that provision of D-chiro-inositol and Myo-inositol can effectively improve insulin action and lower blood glucose, insulin, and triglyceride levels.
We discovered that buckwheat seeds contains large amount of inositol derivatives. We have further developed a proprietary technology that easily and cost-effectively converts the derivatives to active inositol compounds and subsequently isolates the active compounds as a pharmaceutical preparation., which we named Newgenco Buckwheat Seeds Extract. The technology is appropriate for large-scale production. This technology was submitted out for patent application in China in 2001 and 2003, and granted in 2004 and 2005.
It was extracted from natural buckwheat seeds and contains a new kind of insulin sensitizer?D-Chiro-Inositol(DCI)&Myo-Inositol(MI) and demonstrated an excellent safety, efficacy profiles and dominant effect on patients with diabetes, hyperlipidemia, hypertension and obesity
Specification
Description: Buckwheat extract in bulk
Botanical resource: Fagopyrum esculentum Moench, Fagopyrum tatarium Moench
Characteristic: Brown powder, odorless, bitter in taste
Active ingredients:
(1)Total Chiro-inositol: 2000mg/100g;
(2)Total Isoflavone: 600mg/100g
Shelf life: 24month
Manufacture: GMP standard
Quality standard:
Total Chiro-Inositol ?Y1700mg/100g
(D-chiro-inositol and Myo-inositol)
Total Flavones(Rutin as Standard) ?Y460mg/100g
Water ?ü9%
Sulpated Ash ?ü8.0%
Aluminium ?ü2.0mg/kg
Arsenic ?ü1.0 mg/kg
Mercury ?ü0.3mg/kg
Core technology:
We discovered a method of converting large amount of D-CI derivatives in Buckwheat seeds into D-CI monomers, which can be absorbed by human body directly as one of important insulin mediator to improve insulin actions.